Low cell motility induced by hsp27 overexpression decreases osteolytic bone metastases of human breast cancer cells in vivo

被引:8
作者
Lemieux, P
Harvey, J
Guise, T
Dallas, M
Oesterreich, S
Yin, JJ
Selander, K
Fuqua, S
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78284 USA
[2] Angiotech Pharmaceut Inc, Vancouver, BC, Canada
[3] Univ Texas, Hlth Sci Ctr, Dept Med, Div Endocrinol, San Antonio, TX 78284 USA
关键词
D O I
10.1359/jbmr.1999.14.9.1570
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mechanisms controlling the formation of osteolytic bone metastases in patients with breast cancer are still poorly understood. To explore the role of motility in the establishment of osteolytic bone metastases, we have used a model of bone metastasis in which MDA-MB-231 breast cancer cells exhibiting low (hsp27-transfectants) and high (control-transfectant) endogenous cell motility were compared. We found that MDA-MB-231 cells exhibiting low cell motility were less capable of establishing osteolytic lesions. The number and the area of the osteolytic lesions in mice inoculated with low motility cells were both significantly smaller. Histomorphometry of bone lesions also demonstrated less tumor area in mice bearing hsp27 transfectants although there was no difference in the osteoclast number per square millimeter of tumor-bone interface. These data suggest that cell motility may be an important mechanism in the metastatic cascade of breast cancer cells to the bone and that controlling cell motility may be a useful target to prevent the establishment of osteolytic bone metastases.
引用
收藏
页码:1570 / 1575
页数:6
相关论文
共 23 条
[1]  
AARON AD, 1994, JAMA-J AM MED ASSOC, V15, P1206
[2]  
ACHBAROU A, 1994, CANCER RES, V54, P2372
[3]  
ARGUELLO F, 1992, CANCER RES, V52, P2304
[4]  
DECLERCK YA, 1992, CANCER RES, V52, P701
[5]  
Garrido C, 1997, CANCER RES, V57, P2661
[6]  
GUISE T, 1996, J CLIN INVEST, V98, P1
[7]   THE COMBINED EFFECT OF TUMOR-PRODUCED PARATHYROID HORMONE-RELATED PROTEIN AND TRANSFORMING GROWTH-FACTOR-ALPHA ENHANCE HYPERCALCEMIA IN-VIVO AND BONE-RESORPTION IN-VITRO [J].
GUISE, TA ;
YONEDA, T ;
YATES, AJ ;
MUNDY, GR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (01) :40-45
[8]  
Guise TA, 1995, CURR OPIN ENDOCRINOL, V2, P548
[9]   YIGSR, A SYNTHETIC LAMININ PENTAPEPTIDE, INHIBITS EXPERIMENTAL METASTASIS FORMATION [J].
IWAMOTO, Y ;
ROBEY, FA ;
GRAF, J ;
SASAKI, M ;
KLEINMAN, HK ;
YAMADA, Y ;
MARTIN, GR .
SCIENCE, 1987, 238 (4830) :1132-1134
[10]  
KANTOR JD, 1993, CANCER RES, V53, P717